News Website

Merck secures $700 million funding from Blackstone to develop cancer therapy - ET Pharma

Merck secures $700 million funding from Blackstone to develop cancer therapy ET Pharma

Published: Nov. 5, 2025, 12:32 p.m.

Read Full Article

Medical Link Between Hormone Therapy And Period Changes - Saralnama

Medical Link Between Hormone Therapy And Period Changes Saralnama

Published: Nov. 3, 2025, 10:46 p.m.

Read Full Article

Frontline Considerations for Immunotherapy in Endometrial Cancer - OncLive

Frontline Considerations for Immunotherapy in Endometrial Cancer OncLive

Published: Nov. 3, 2025, 1:36 p.m.

Read Full Article

Effects of miR-210-3p/SDF2 and miR-31-5p/FGF7 from hypoxic endometrial exosomes on UCB-MSC proliferation, migration, and differentiation - Stem Cell Research & Therapy

Effects of miR-210-3p/SDF2 and miR-31-5p/FGF7 from hypoxic endometrial exosomes on UCB-MSC proliferation, migration, and differentiation Stem Cell Research & Therapy

Published: Nov. 3, 2025, 10:18 a.m.

Read Full Article

Mechanisms and applications of mesenchymal stem cell exosomes in enhancing fertility - Stem Cell Research & Therapy

Mechanisms and applications of mesenchymal stem cell exosomes in enhancing fertility Stem Cell Research & Therapy

Published: Oct. 28, 2025, 2:15 p.m.

Read Full Article

Michelle Wise, MD, discusses levonorgestrel IUD offering effective endometrial protection during hormone therapy - Contemporary OB/GYN

Michelle Wise, MD, discusses levonorgestrel IUD offering effective endometrial protection during hormone therapy Contemporary OB/GYN

Published: Oct. 23, 2025, 8:33 p.m.

Read Full Article

WES-Aneuploidy Scores May Be Prognostic for Immunotherapy in dMMR Endometrial Cancer - OncLive

WES-Aneuploidy Scores May Be Prognostic for Immunotherapy in dMMR Endometrial Cancer OncLive

Published: Oct. 23, 2025, 6:03 p.m.

Read Full Article

Dana-Farber Research Uncovers Potential Targeted Therapy for Endometrial Cancer - Dana-Farber Cancer Institute

Dana-Farber Research Uncovers Potential Targeted Therapy for Endometrial Cancer Dana-Farber Cancer Institute

Published: Oct. 21, 2025, 9 a.m.

Read Full Article

Female Reproductive Digital Therapy Market Is Projected To Reach a Valuation of USD 12 Billion by 2035, Growing at a CAGR of 19.4% - industrytoday.co.uk

Female Reproductive Digital Therapy Market Is Projected To Reach a Valuation of USD 12 Billion by 2035, Growing at a CAGR of 19.4% industrytoday.co.uk

Published: Oct. 20, 2025, 10:14 a.m.

Read Full Article

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - The AI Journal

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen The AI Journal

Published: Oct. 18, 2025, 10:28 a.m.

Read Full Article

Latest Articles

Merck secures $700 million funding from Blackstone to develop cancer therapy - ET Pharma

Medical Link Between Hormone Therapy And Period Changes - Saralnama

Frontline Considerations for Immunotherapy in Endometrial Cancer - OncLive

Effects of miR-210-3p/SDF2 and miR-31-5p/FGF7 from hypoxic endometrial exosomes on UCB-MSC proliferation, migration, and differentiation - Stem Cell Research & Therapy

Mechanisms and applications of mesenchymal stem cell exosomes in enhancing fertility - Stem Cell Research & Therapy

Michelle Wise, MD, discusses levonorgestrel IUD offering effective endometrial protection during hormone therapy - Contemporary OB/GYN

WES-Aneuploidy Scores May Be Prognostic for Immunotherapy in dMMR Endometrial Cancer - OncLive

Dana-Farber Research Uncovers Potential Targeted Therapy for Endometrial Cancer - Dana-Farber Cancer Institute

Female Reproductive Digital Therapy Market Is Projected To Reach a Valuation of USD 12 Billion by 2035, Growing at a CAGR of 19.4% - industrytoday.co.uk

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - The AI Journal

Subscribe to Our Newsletter